NeoGenomics (NEO)
(Delayed Data from NSDQ)
$15.57 USD
+0.06 (0.39%)
Updated May 7, 2024 04:00 PM ET
After-Market: $15.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
NEO 15.57 +0.06(0.39%)
Will NEO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NEO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NEO
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
NEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Other News for NEO
Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
NeoGenomics price target lowered by $2 at BTIG, here's why
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
Buy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth Prospects
Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls